98%
921
2 minutes
20
Colorectal cancer (CRC) remains a significant global health challenge, as current treatments such as surgery and chemotherapy are limited by poor precision, severe side effects, and the complex tumor microenvironment. Photothermal therapy (PTT) offers a promising alternative; however, conventional photothermal agents largely rely on synthetic materials, raising concerns about stability, toxicity, and metabolic degradation. To overcome these limitations, this study aimed to develop a biocompatible photothermal nanoplatform using iodine (I)-loaded acetylated starch nanoparticles (ASt NPs). The helical structure of ASt efficiently encapsulated I, facilitating a chromogenic interaction that provides near-infrared (NIR) absorbance and enables the NPs to function as intrinsic photothermal agents for PTT. Under NIR irradiation, these NPs generated localized heating, enabling precise temperature modulation through reversible color changes. The ASt NPs also encapsulated the IDO1 inhibitor NLG919 (IN@ASt NPs), enhancing immune modulation by downregulating IDO1 expression and reducing PTT-induced immunosuppression. This synergy induced immunogenic cell death, activated strong antitumor immunity, and inhibited lung metastasis in CRC models. Thus, this innovative platform leverages the biocompatibility of carbohydrate-based materials to address key challenges in CRC therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2025.146976 | DOI Listing |
Cancer Epidemiol Biomarkers Prev
September 2025
Brigham and Women's Hospital, Boston, MA, United States.
Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.
Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.
JACC Case Rep
September 2025
Department of Cardiovascular Surgery, Nagoya Heart Center, Nagoya, Japan.
Background: Capecitabine, an oral prodrug of 5-fluorouracil, is widely used for gastrointestinal malignancies. While its coronary toxicity is well documented, large-vessel complications such as aortic dissection are rarely reported.
Case Summary: We present a 65-year-old man with colorectal cancer who developed Stanford type A aortic dissection 3 days after initiating adjuvant capecitabine therapy.
Br J Surg
September 2025
Department of Digestive Surgery, CARPEM Comprehensive Cancer Centre, Georges-Pompidou European Hospital, AP-HP, Université Paris-Cité, Paris, France.
Rep Pract Oncol Radiother
August 2025
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, Poznan, Poland.
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.
View Article and Find Full Text PDFFront Chem
August 2025
Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Jinan University, Guangzhou, China.
Introduction: Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects. Erianin, a natural compound from Chinese medicine Lindl, demonstrates significant potential in both tumor growth inhibition and chemotherapy toxicity reduction.
View Article and Find Full Text PDF